These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2297717

  • 1. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody.
    Siegel JA, Pawlyk DA, Lee RE, Sasso NL, Horowitz JA, Sharkey RM, Goldenberg DM.
    Cancer Res; 1990 Feb 01; 50(3 Suppl):1039s-1042s. PubMed ID: 2297717
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM.
    J Nucl Med; 1998 Jan 01; 39(1):34-42. PubMed ID: 9443735
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 5. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
    Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM.
    Int J Rad Appl Instrum B; 1989 Oct 01; 16(6):553-9. PubMed ID: 2481657
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

  • 8. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 01; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 9. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Jun 01; 38(6):858-70. PubMed ID: 9189130
    [Abstract] [Full Text] [Related]

  • 10. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
    Sharkey RM, Pykett MJ, Siegel JA, Alger EA, Primus FJ, Goldenberg DM.
    Cancer Res; 1987 Nov 01; 47(21):5672-7. PubMed ID: 3664474
    [Abstract] [Full Text] [Related]

  • 11. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS, Hird V, Snook D, Sullivan M, Myers MJ, Epenetos AA.
    Int J Cancer Suppl; 1988 Nov 01; 3():71-6. PubMed ID: 3209303
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C, Lindén O, Tennvall J, Wingårdh K, Strand SE.
    Acta Oncol; 2005 Nov 01; 44(6):579-88. PubMed ID: 16165917
    [Abstract] [Full Text] [Related]

  • 13. Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies.
    DeNardo DA, DeNardo GL, Yuan A, Shen S, DeNardo SJ, Macey DJ, Lamborn KR, Mahe M, Groch MW, Erwin WD.
    J Nucl Med; 1996 Dec 01; 37(12):1970-5. PubMed ID: 8970516
    [Abstract] [Full Text] [Related]

  • 14. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM.
    J Nucl Med; 1997 Mar 01; 38(3):409-18. PubMed ID: 9074529
    [Abstract] [Full Text] [Related]

  • 15. Treatment of intracranial human glioma xenografts with 131I-labeled anti-tenascin monoclonal antibody 81C6.
    Lee Y, Bullard DE, Humphrey PA, Colapinto EV, Friedman HS, Zalutsky MR, Coleman RE, Bigner DD.
    Cancer Res; 1988 May 15; 48(10):2904-10. PubMed ID: 2452014
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, Goldenberg DM.
    J Nucl Med; 1996 Sep 15; 37(9):1504-10. PubMed ID: 8790202
    [Abstract] [Full Text] [Related]

  • 17. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
    DeNardo GL, DeNardo SJ, Shen S, DeNardo DA, Mirick GR, Macey DJ, Lamborn KR.
    J Nucl Med; 1999 Aug 15; 40(8):1317-26. PubMed ID: 10450684
    [Abstract] [Full Text] [Related]

  • 18. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
    Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
    [Abstract] [Full Text] [Related]

  • 19. Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.
    Buchegger F, Pfister C, Fournier K, Prevel F, Schreyer M, Carrel S, Mach JP.
    J Clin Invest; 1989 May 15; 83(5):1449-56. PubMed ID: 2708519
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
    Juweid ME, Stadtmauer E, Hajjar G, Sharkey RM, Suleiman S, Luger S, Swayne LC, Alavi A, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 15; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.